Figures & data
Figure 1 Schematic diagram for preparation of the Fe3O4-SF nanoparticles.
Abbreviations: HPLC, high-performance liquid chromatography; SF, silk fibroin.
![Figure 1 Schematic diagram for preparation of the Fe3O4-SF nanoparticles.Abbreviations: HPLC, high-performance liquid chromatography; SF, silk fibroin.](/cms/asset/58dda58f-2e46-411b-98cd-5999c5abb661/dijn_a_85999_f0001_b.jpg)
Figure 2 The experimental setup for permeation studies.
Notes: (A) Diffusion cell with stationary magnetic field; (B) diffusion cell with alternating magnetic field; and (C) diffusion cell with stationary/alternating magnetic fields.
![Figure 2 The experimental setup for permeation studies.Notes: (A) Diffusion cell with stationary magnetic field; (B) diffusion cell with alternating magnetic field; and (C) diffusion cell with stationary/alternating magnetic fields.](/cms/asset/1bbb58c7-1513-4b85-86df-718e57bd6463/dijn_a_85999_f0002_c.jpg)
Figure 3 SEM photographs of nanoparticles.
Notes: (A) Fe3O4-SF nanoparticles with an Fe3O4/SF ratio of 3:20; (B) MTX-Fe3O4-SF nanoparticles (drug load =20%).
Abbreviations: MTX, methotrexate; SEM, scanning electron microscope; SF, silk fibroin.
![Figure 3 SEM photographs of nanoparticles.Notes: (A) Fe3O4-SF nanoparticles with an Fe3O4/SF ratio of 3:20; (B) MTX-Fe3O4-SF nanoparticles (drug load =20%).Abbreviations: MTX, methotrexate; SEM, scanning electron microscope; SF, silk fibroin.](/cms/asset/6696484d-7128-4884-9fb7-ef453ba56130/dijn_a_85999_f0003_c.jpg)
Figure 4 Drug load and encapsulation efficiency of MTX-Fe3O4-SF nanoparticles.
Abbreviations: MTX, methotrexate; SF, silk fibroin.
![Figure 4 Drug load and encapsulation efficiency of MTX-Fe3O4-SF nanoparticles.Abbreviations: MTX, methotrexate; SF, silk fibroin.](/cms/asset/17e125ed-29d3-4765-adec-ecba20ae58f3/dijn_a_85999_f0004_b.jpg)
Figure 5 The cumulative permeation of MTX across the skin.
Notes: @, #, and & indicate the statistical significant difference when compared with the stationary magnetic field, the alternating magnetic field, and the stationary/alternating magnetic field, respectively. P<0.05.
Abbreviations: MTX, methotrexate; NPs, nanoparticles.
![Figure 5 The cumulative permeation of MTX across the skin.Notes: @, #, and & indicate the statistical significant difference when compared with the stationary magnetic field, the alternating magnetic field, and the stationary/alternating magnetic field, respectively. P<0.05.Abbreviations: MTX, methotrexate; NPs, nanoparticles.](/cms/asset/0462ec12-cb82-4e49-af12-8ccbe82de67b/dijn_a_85999_f0005_c.jpg)
Figure 6 Laser scanning microscope images of the penetration of FITC-Fe3O4-SF nanoparticles.
Notes: (A) Control; (B) stationary magnetic field; (C) alternating magnetic field; and (D) stationary/alternating magnetic fields.
Abbreviations: FITC, fluorescein isothiocyanate; SF, silk fibroin.
![Figure 6 Laser scanning microscope images of the penetration of FITC-Fe3O4-SF nanoparticles.Notes: (A) Control; (B) stationary magnetic field; (C) alternating magnetic field; and (D) stationary/alternating magnetic fields.Abbreviations: FITC, fluorescein isothiocyanate; SF, silk fibroin.](/cms/asset/3d76629e-c582-4adf-8f97-774dee5d9b2a/dijn_a_85999_f0006_c.jpg)
Figure 7 ATR-FTIR spectra of skin.
Notes: 1: Control. 2: Stationary magnetic field. 3: Alternating magnetic field. 4: Stationary/alternating magnetic fields. (A) ATR-FTIR spectra of skin and (B) ATR-FTIR spectra of stratum corneum in the C-H stretching region between 2,800 and 2,950 cm−1.
Abbreviation: ATR-FTIR, attenuated total reflection Fourier-transform infrared spectroscopy.
![Figure 7 ATR-FTIR spectra of skin.Notes: 1: Control. 2: Stationary magnetic field. 3: Alternating magnetic field. 4: Stationary/alternating magnetic fields. (A) ATR-FTIR spectra of skin and (B) ATR-FTIR spectra of stratum corneum in the C-H stretching region between 2,800 and 2,950 cm−1.Abbreviation: ATR-FTIR, attenuated total reflection Fourier-transform infrared spectroscopy.](/cms/asset/7b7fceeb-61d5-44eb-a1c5-404723613cf6/dijn_a_85999_f0007_c.jpg)
Figure S1 SEM photographs of Fe3O4-SF nanoparticles in different ratios of SF/Fe3O4.
Notes: SF/Fe3O4= (A) 40:3; (B) 20:3; (C) 10:3; (D) 5:3.
Abbreviations: SEM, scanning electron microscope; SF, silk fibroin.
![Figure S1 SEM photographs of Fe3O4-SF nanoparticles in different ratios of SF/Fe3O4.Notes: SF/Fe3O4= (A) 40:3; (B) 20:3; (C) 10:3; (D) 5:3.Abbreviations: SEM, scanning electron microscope; SF, silk fibroin.](/cms/asset/e25d74ae-8b89-4591-8d5a-73424efaa970/dijn_a_85999_sf0001_b.jpg)
Figure S2 Particle size distribution.
Notes: (A) Fe3O4-SF nanoparticles (SF/Fe3O4=20:3) and (B) MTX-Fe3O4-SF nanoparticles.
Abbreviations: MTX, methotrexate; SF, silk fibroin.
![Figure S2 Particle size distribution.Notes: (A) Fe3O4-SF nanoparticles (SF/Fe3O4=20:3) and (B) MTX-Fe3O4-SF nanoparticles.Abbreviations: MTX, methotrexate; SF, silk fibroin.](/cms/asset/3dfec0b7-bf53-41ba-accb-38468a7fb897/dijn_a_85999_sf0002_c.jpg)
Figure S3 Histopathological analyses of skin.
Notes: (A) Control; (B) stationary magnetic field; (C) alternating magnetic field; and (D) stationary/alternating magnetic field.
![Figure S3 Histopathological analyses of skin.Notes: (A) Control; (B) stationary magnetic field; (C) alternating magnetic field; and (D) stationary/alternating magnetic field.](/cms/asset/a9420332-d126-4f8f-b8d0-d45cf68f7a2c/dijn_a_85999_sf0003_c.jpg)
Table S1 Permeation coefficient of MTX solution and MTX-Fe3O4-SF NPs